{
    "info": {
        "nct_id": "NCT06007937",
        "official_title": "A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers",
        "inclusion_criteria": "* Written informed consent\n* Age >18 years old\n* Metastatic or recurrent, biopsy-proven non-small cell lung cancer\n* ALK fusion identified by next generation sequencing (NGS) or IHC on material obtained from tumor or plasma\n* Measurable (RECIST 1.1) indicator lesion not previously irradiated\n* Karnofsky performance status (KPS) ≥ 70%\n* Adequate organ function defined as follows: ANC ≥1.5 × 10^9 /L, platelets ≥100 × 10^9/L, hemoglobin ≥ 9 g/dL, INR ≤ 1.5, PTT or aPTT <1.5x ULN, total bilirubin ≤ 1.5 × ULN (Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted), AST ≤ 3 × ULN, ALT ≤ 3 × ULN or ≤ 5 x ULN in the setting of liver metastases, Cr ≤1.5 ULN or CrCl ≥ 40 mL/min. If Cr is\n\n  ≥ 1.5x ULN, a 24-hr urine collection to calculate creatinine clearance must be performed\n\n  °The patient's urinary protein is ≤1+ on dipstick or routine urinalysis (UA); if urine dipstick or routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol).\n* Patients on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin for a minimum of 14 days prior to trial enrollment without signs of active bleeding or pathological condition that carries a high risk of bleeding (eg, tumor invading major vessels or known varices). Patients on warfarin must have an INR ≤ 3.0\n* Patients must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] version 5 Grade ≤1) from the acute effects of prior therapy, except for residual alopecia or peripheral neuropathy (up to grade 2 allowed)prior to start of therapy\n* Patients in cohort 1 will be treatment-naïve in the metastatic setting. Prior treatment with adjuvant chemotherapy is allowed\n* Patients in cohort 2 will have progressed or be intolerant of at least one second generation ALK TKI, including alectinib, brigatinib, or ceritinib.\n* Patients may have received multiple ALK TKIs as well as chemotherapy, but one of these treatments must have been with a second-generation ALK TKI.\n* Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods).\n* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy.\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
        "exclusion_criteria": "* Prior lorlatinib or ramucirumab exposure\n* Symptomatic, unstable brain metastasis requiring therapy with steroids or radiation therapy. Patients with clinically stable brain metastases (previously treated or untreated) are eligible\n* Women who are breastfeeding or pregnant\n* Major radiotherapy within 2 weeks of starting treatment on protocol\n* Major surgery within 4 weeks of starting treatment on protocol or minor surgery/subcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy\n* Less than 3 weeks since previous chemotherapy, 4 weeks since immunotherapy, and 2 weeks from any investigational therapy\n* Significant bleeding disorders or grade ≥3 bleeding episode within 12 weeks prior to enrollment. Patients with history of gross hemoptysis (defined as bright red blood of ≥1/2 teaspoon) within 8 weeks prior to enrollment will be excluded\n* New or history of diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE) or other significant thromboembolic event in the 12 weeks prior to first dose of protocol therapy. Patients with thromboembolic events diagnosed >12 weeks prior to protocol therapy are eligible if on stable doses of anticoagulation as outlined above. Venous port or catheter thrombosis or superficial venous thrombosis are not considered significant events\n* GI perforation and/or fistula or bowel obstruction within 6 months or risk factors for perforation prior to enrollment\n* Child-Pugh B or greater cirrhosis or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis\n* Uncontrolled hypertension, defined as systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg, prior to initiating study treatment, despite hypertensive intervention\n* Serious or non-healing wound, ulcer or bone fracture within 28 days of enrollment\n* Radiologically documented evidence of major blood vessel invasion or encasement by cancer or radiographic evidence of intratumor cavitation\n* Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.\n* Arterial thrombotic event or arterial thromboembolic event, including myocardial infarction, unstable angina, congestive heart failure ≥ NYHA class III, cerebrovascular accident or transient ischemic attack, within 6 months prior to enrollment\n* Planned elective or major surgery during the trial\n* Chronic therapy with any of the following within 7 days of enrollment:\n\n  * Antiplatelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide)\n  * Aspirin up to 325 mg/day is permitted\n* Serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the patient's ability to complete the study or sign an informed consent document\n* Patients with unavoidable strong CYP3A inducer or inhibitor use (see table 15.4 for list of agents)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Adequate organ function defined as follows: ANC ≥1.5 × 10^9 /L, platelets ≥100 × 10^9/L, hemoglobin ≥ 9 g/dL, INR ≤ 1.5, PTT or aPTT <1.5x ULN, total bilirubin ≤ 1.5 × ULN (Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted), AST ≤ 3 × ULN, ALT ≤ 3 × ULN or ≤ 5 x ULN in the setting of liver metastases, Cr ≤1.5 ULN or CrCl ≥ 40 mL/min. If Cr is",
            "criterions": [
                {
                    "exact_snippets": "ANC ≥1.5 × 10^9 /L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelets ≥100 × 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hemoglobin ≥ 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "INR ≤ 1.5",
                    "criterion": "international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PTT or aPTT <1.5x ULN",
                    "criterion": "PTT or aPTT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total bilirubin ≤ 1.5 × ULN (Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "special case (Gilbert's syndrome)",
                            "expected_value": "total bilirubin ≤2.0 × ULN and direct bilirubin within normal limits"
                        }
                    ]
                },
                {
                    "exact_snippets": "AST ≤ 3 × ULN",
                    "criterion": "AST (aspartate aminotransferase)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ≤ 3 × ULN or ≤ 5 x ULN in the setting of liver metastases",
                    "criterion": "ALT (alanine aminotransferase)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "special case (liver metastases)",
                            "expected_value": "ALT ≤ 5 × ULN"
                        }
                    ]
                },
                {
                    "exact_snippets": "Cr ≤1.5 ULN or CrCl ≥ 40 mL/min",
                    "criterion": "creatinine or creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity (creatinine)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity (creatinine clearance)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >18 years old",
            "criterions": [
                {
                    "exact_snippets": "Age >18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy.",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative serum pregnancy test within 7 days prior to first dose of protocol therapy",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to first dose of protocol therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] version 5 Grade ≤1) from the acute effects of prior therapy, except for residual alopecia or peripheral neuropathy (up to grade 2 allowed)prior to start of therapy",
            "criterions": [
                {
                    "exact_snippets": "Patients must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] version 5 Grade ≤1) from the acute effects of prior therapy",
                    "criterion": "recovery from acute effects of prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE v5 Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for residual alopecia or peripheral neuropathy (up to grade 2 allowed)",
                    "criterion": "residual alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE v5 Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for residual alopecia or peripheral neuropathy (up to grade 2 allowed)",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE v5 Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": "written"
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "≥ 1.5x ULN, a 24-hr urine collection to calculate creatinine clearance must be performed",
            "criterions": [
                {
                    "exact_snippets": "≥ 1.5x ULN, a 24-hr urine collection to calculate creatinine clearance must be performed",
                    "criterion": "creatinine clearance (via 24-hr urine collection)",
                    "requirements": [
                        {
                            "requirement_type": "testing requirement",
                            "expected_value": "must be performed if value is ≥ 1.5x ULN"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ALK fusion identified by next generation sequencing (NGS) or IHC on material obtained from tumor or plasma",
            "criterions": [
                {
                    "exact_snippets": "ALK fusion identified by next generation sequencing (NGS) or IHC",
                    "criterion": "ALK fusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "next generation sequencing (NGS)",
                                "IHC"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "material obtained from tumor or plasma",
                    "criterion": "sample material",
                    "requirements": [
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "tumor",
                                "plasma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients in cohort 1 will be treatment-naïve in the metastatic setting. Prior treatment with adjuvant chemotherapy is allowed",
            "criterions": [
                {
                    "exact_snippets": "Patients in cohort 1 will be treatment-naïve in the metastatic setting",
                    "criterion": "treatment in the metastatic setting",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with adjuvant chemotherapy is allowed",
                    "criterion": "prior adjuvant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastatic or recurrent, biopsy-proven non-small cell lung cancer",
            "criterions": [
                {
                    "exact_snippets": "Metastatic or recurrent",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "metastatic",
                                "recurrent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy-proven",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "non-small cell lung cancer",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "non-small cell lung cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "°The patient's urinary protein is ≤1+ on dipstick or routine urinalysis (UA); if urine dipstick or routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours to allow participation in this protocol).",
            "criterions": [
                {
                    "exact_snippets": "urinary protein is ≤1+ on dipstick or routine urinalysis (UA)",
                    "criterion": "urinary protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "+"
                            }
                        },
                        {
                            "requirement_type": "test_method",
                            "expected_value": [
                                "dipstick",
                                "routine urinalysis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if urine dipstick or routine analysis is ≥2+, a 24-hour urine collection for protein must demonstrate <1000 mg of protein in 24 hours",
                    "criterion": "urinary protein (24-hour urine collection)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1000,
                                "unit": "mg/24 hours"
                            }
                        },
                        {
                            "requirement_type": "test_method",
                            "expected_value": "24-hour urine collection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable (RECIST 1.1) indicator lesion not previously irradiated",
            "criterions": [
                {
                    "exact_snippets": "Measurable (RECIST 1.1) indicator lesion",
                    "criterion": "indicator lesion",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "indicator lesion not previously irradiated",
                    "criterion": "indicator lesion",
                    "requirements": [
                        {
                            "requirement_type": "prior irradiation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may have received multiple ALK TKIs as well as chemotherapy, but one of these treatments must have been with a second-generation ALK TKI.",
            "criterions": [
                {
                    "exact_snippets": "Patients may have received multiple ALK TKIs as well as chemotherapy",
                    "criterion": "prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment types",
                            "expected_value": [
                                "ALK TKI",
                                "chemotherapy"
                            ]
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "one of these treatments must have been with a second-generation ALK TKI",
                    "criterion": "prior treatment with second-generation ALK TKI",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "second-generation ALK TKI"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin for a minimum of 14 days prior to trial enrollment without signs of active bleeding or pathological condition that carries a high risk of bleeding (eg, tumor invading major vessels or known varices). Patients on warfarin must have an INR ≤ 3.0",
            "criterions": [
                {
                    "exact_snippets": "Patients on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin for a minimum of 14 days prior to trial enrollment",
                    "criterion": "anticoagulation therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "medication type",
                            "expected_value": [
                                "oral anticoagulant",
                                "low molecular weight heparin"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without signs of active bleeding",
                    "criterion": "active bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "pathological condition that carries a high risk of bleeding (eg, tumor invading major vessels or known varices)",
                    "criterion": "pathological condition with high risk of bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients on warfarin must have an INR ≤ 3.0",
                    "criterion": "INR (for patients on warfarin)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky performance status (KPS) ≥ 70%",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance status (KPS) ≥ 70%",
                    "criterion": "Karnofsky performance status (KPS)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods).",
            "criterions": [
                {
                    "exact_snippets": "the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)",
                    "criterion": "reproductive status or contraception use",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "postmenopausal",
                                "surgically sterile"
                            ]
                        },
                        {
                            "requirement_type": "contraception use",
                            "expected_value": "using effective contraception (hormonal or barrier methods)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients in cohort 2 will have progressed or be intolerant of at least one second generation ALK TKI, including alectinib, brigatinib, or ceritinib.",
            "criterions": [
                {
                    "exact_snippets": "Patients in cohort 2 will have progressed or be intolerant of at least one second generation ALK TKI",
                    "criterion": "treatment with second generation ALK TKI",
                    "requirements": [
                        {
                            "requirement_type": "treatment history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression or intolerance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of agents",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "second generation ALK TKI"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including alectinib, brigatinib, or ceritinib",
                    "criterion": "second generation ALK TKI agents",
                    "requirements": [
                        {
                            "requirement_type": "agent examples",
                            "expected_value": [
                                "alectinib",
                                "brigatinib",
                                "ceritinib"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 19 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 19 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 19,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Planned elective or major surgery during the trial",
            "criterions": [
                {
                    "exact_snippets": "Planned elective or major surgery during the trial",
                    "criterion": "planned elective or major surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the trial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Antiplatelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide)",
            "criterions": [
                {
                    "exact_snippets": "Antiplatelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide)",
                    "criterion": "antiplatelet agent use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "agent_names",
                            "expected_value": [
                                "clopidogrel",
                                "ticlopidine",
                                "dipyridamole",
                                "anagrelide"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Less than 3 weeks since previous chemotherapy, 4 weeks since immunotherapy, and 2 weeks from any investigational therapy",
            "criterions": [
                {
                    "exact_snippets": "Less than 3 weeks since previous chemotherapy",
                    "criterion": "time since previous chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "4 weeks since immunotherapy",
                    "criterion": "time since immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "2 weeks from any investigational therapy",
                    "criterion": "time since investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious uncontrolled medical disorders or psychological conditions that would, in the opinion of the investigator, limit the patient's ability to complete the study or sign an informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Serious uncontrolled medical disorders",
                    "criterion": "medical disorders",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychological conditions",
                    "criterion": "psychological conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that would, in the opinion of the investigator, limit the patient's ability to complete the study",
                    "criterion": "ability to complete the study",
                    "requirements": [
                        {
                            "requirement_type": "limitation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that would, in the opinion of the investigator, limit the patient's ability to...sign an informed consent document",
                    "criterion": "ability to sign an informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "limitation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant bleeding disorders or grade ≥3 bleeding episode within 12 weeks prior to enrollment. Patients with history of gross hemoptysis (defined as bright red blood of ≥1/2 teaspoon) within 8 weeks prior to enrollment will be excluded",
            "criterions": [
                {
                    "exact_snippets": "Significant bleeding disorders",
                    "criterion": "bleeding disorders",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "grade ≥3 bleeding episode within 12 weeks prior to enrollment",
                    "criterion": "bleeding episode",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": "within 12 weeks prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of gross hemoptysis (defined as bright red blood of ≥1/2 teaspoon) within 8 weeks prior to enrollment",
                    "criterion": "gross hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "teaspoon"
                            }
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": "within 8 weeks prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Child-Pugh B or greater cirrhosis or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis",
            "criterions": [
                {
                    "exact_snippets": "Child-Pugh B or greater cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "Child-Pugh classification",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Child-Pugh class (A=1, B=2, C=3)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis (any degree) and a history of hepatic encephalopathy",
                    "criterion": "hepatic encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "cirrhosis"
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis (any degree) and ... clinically meaningful ascites resulting from cirrhosis",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "clinical meaningfulness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "cirrhosis"
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "cirrhosis"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "diuretics",
                                "paracentesis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major radiotherapy within 2 weeks of starting treatment on protocol",
            "criterions": [
                {
                    "exact_snippets": "Major radiotherapy within 2 weeks of starting treatment on protocol",
                    "criterion": "major radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to protocol treatment start",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiologically documented evidence of major blood vessel invasion or encasement by cancer or radiographic evidence of intratumor cavitation",
            "criterions": [
                {
                    "exact_snippets": "Radiologically documented evidence of major blood vessel invasion or encasement by cancer",
                    "criterion": "major blood vessel invasion or encasement by cancer",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": "radiologically documented"
                        }
                    ]
                },
                {
                    "exact_snippets": "radiographic evidence of intratumor cavitation",
                    "criterion": "intratumor cavitation",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": "radiographic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Arterial thrombotic event or arterial thromboembolic event, including myocardial infarction, unstable angina, congestive heart failure ≥ NYHA class III, cerebrovascular accident or transient ischemic attack, within 6 months prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Arterial thrombotic event ... within 6 months prior to enrollment",
                    "criterion": "arterial thrombotic event",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "arterial thromboembolic event ... within 6 months prior to enrollment",
                    "criterion": "arterial thromboembolic event",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction ... within 6 months prior to enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina ... within 6 months prior to enrollment",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure ≥ NYHA class III ... within 6 months prior to enrollment",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA_class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        },
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident ... within 6 months prior to enrollment",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "transient ischemic attack ... within 6 months prior to enrollment",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior lorlatinib or ramucirumab exposure",
            "criterions": [
                {
                    "exact_snippets": "Prior lorlatinib ... exposure",
                    "criterion": "lorlatinib exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior ... ramucirumab exposure",
                    "criterion": "ramucirumab exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic, unstable brain metastasis requiring therapy with steroids or radiation therapy. Patients with clinically stable brain metastases (previously treated or untreated) are eligible",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic, unstable brain metastasis requiring therapy with steroids or radiation therapy",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        },
                        {
                            "requirement_type": "requires therapy",
                            "expected_value": [
                                "steroids",
                                "radiation therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with clinically stable brain metastases (previously treated or untreated) are eligible",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "clinically stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension, defined as systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg, prior to initiating study treatment, despite hypertensive intervention",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension, defined as systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg, prior to initiating study treatment, despite hypertensive intervention",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 160,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to initiating study treatment"
                        },
                        {
                            "requirement_type": "response to intervention",
                            "expected_value": "despite hypertensive intervention"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* GI perforation and/or fistula or bowel obstruction within 6 months or risk factors for perforation prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "GI perforation ... within 6 months",
                    "criterion": "GI perforation",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "fistula ... within 6 months",
                    "criterion": "fistula",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bowel obstruction within 6 months",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "risk factors for perforation prior to enrollment",
                    "criterion": "risk factors for perforation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks of starting treatment on protocol or minor surgery/subcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of starting treatment on protocol",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "minor surgery/subcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "minor surgery/subcutaneous venous access device placement within 7 days prior to the first dose of protocol therapy",
                    "criterion": "subcutaneous venous access device placement",
                    "requirements": [
                        {
                            "requirement_type": "time since device placement",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chronic therapy with any of the following within 7 days of enrollment:",
            "criterions": [
                {
                    "exact_snippets": "Chronic therapy with any of the following within 7 days of enrollment",
                    "criterion": "chronic therapy with specified agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are breastfeeding or pregnant",
            "criterions": [
                {
                    "exact_snippets": "Women who are breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "breastfeeding"
                        }
                    ]
                },
                {
                    "exact_snippets": "Women who are ... pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "pregnant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment)",
                    "criterion": "systemic bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous antibiotics at time of initiating study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "fungal infection",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "detectable viral infection (such as known human immunodeficiency virus positivity with known active hepatitis B or C [for example, hepatitis B surface antigen positive]",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known human immunodeficiency virus positivity",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis B or C [for example, hepatitis B surface antigen positive]",
                    "criterion": "active hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with unavoidable strong CYP3A inducer or inhibitor use (see table 15.4 for list of agents)",
            "criterions": [
                {
                    "exact_snippets": "unavoidable strong CYP3A inducer or inhibitor use",
                    "criterion": "CYP3A inducer or inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "strength",
                            "expected_value": "strong"
                        },
                        {
                            "requirement_type": "avoidability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious or non-healing wound, ulcer or bone fracture within 28 days of enrollment",
            "criterions": [
                {
                    "exact_snippets": "Serious ... wound ... within 28 days of enrollment",
                    "criterion": "serious wound",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "non-healing wound ... within 28 days of enrollment",
                    "criterion": "non-healing wound",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcer ... within 28 days of enrollment",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bone fracture within 28 days of enrollment",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspirin up to 325 mg/day is permitted",
            "criterions": [
                {
                    "exact_snippets": "Aspirin up to 325 mg/day is permitted",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "maximum dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* New or history of diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE) or other significant thromboembolic event in the 12 weeks prior to first dose of protocol therapy. Patients with thromboembolic events diagnosed >12 weeks prior to protocol therapy are eligible if on stable doses of anticoagulation as outlined above. Venous port or catheter thrombosis or superficial venous thrombosis are not considered significant events",
            "criterions": [
                {
                    "exact_snippets": "New or history of diagnosis of deep vein thrombosis (DVT) ... in the 12 weeks prior to first dose of protocol therapy",
                    "criterion": "deep vein thrombosis (DVT)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "New or history of diagnosis of pulmonary embolism (PE) ... in the 12 weeks prior to first dose of protocol therapy",
                    "criterion": "pulmonary embolism (PE)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "New or history of diagnosis of ... other significant thromboembolic event in the 12 weeks prior to first dose of protocol therapy",
                    "criterion": "other significant thromboembolic event",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "thromboembolic events diagnosed >12 weeks prior to protocol therapy are eligible if on stable doses of anticoagulation as outlined above",
                    "criterion": "thromboembolic event diagnosed >12 weeks prior",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "anticoagulation_status",
                            "expected_value": "stable doses"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}